8-amino-3(benzyloxy)-2-[4-(benzyloxy)-3-bromophenyl]-6-methyl-4H-chromen-4-one | 372102-34-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 8-amino-3(benzyloxy)-2-[4-(benzyloxy)-3-bromophenyl]-6-methyl-4H-chromen-4-one
• 英文别名: 8-Amino-2-(3-bromo-4-phenylmethoxyphenyl)-6-methyl-3-phenylmethoxychromen-4-one
• CAS: 372102-34-6
• 化学式: C₃₀H₂₄BrNO₄
• 分子量: 542.429
• InChiKey: ISEWQGYSUNNCFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-amino-3(benzyloxy)-2-[4-(benzyloxy)-3-bromophenyl]-6-methyl-4H-chromen-4-one 在 4-二甲氨基吡啶 、 1,1'-双(二苯基膦)二茂铁 、 tris(dibenzylideneacetone)dipalladium (0) 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(benzyloxy)-5-[3-(benzyloxy)-8-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-6-methyl-4-oxo-4H-chromen-2-yl]benzonitrile
  参考文献：
  名称：

  3-Hydroxychromones as cyclin-dependent kinase inhibitors: Synthesis and biological evaluation

  摘要：

  A novel series of 3-hydroxychrornones were prepared and found to be CDK inhibitors. lsothiazolidine 1,1-dioxide analogues showed potent CDK1 and CDK2 inhibitory activities and inhibited proliferation of EJ, HCT 116, SW620, and MDAMB468 cancer cells. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.011
• 作为产物：
  描述：

  4-(苄氧基)-3-溴苯甲醛 在 4-二甲氨基吡啶 、 sodium hydroxide 、 二碳酸二叔丁酯 、 双氧水 、 potassium carbonate 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 丙酮 为溶剂， 生成 8-amino-3(benzyloxy)-2-[4-(benzyloxy)-3-bromophenyl]-6-methyl-4H-chromen-4-one
  参考文献：
  名称：

  3-Hydroxychromones as cyclin-dependent kinase inhibitors: Synthesis and biological evaluation

  摘要：

  A novel series of 3-hydroxychrornones were prepared and found to be CDK inhibitors. lsothiazolidine 1,1-dioxide analogues showed potent CDK1 and CDK2 inhibitory activities and inhibited proliferation of EJ, HCT 116, SW620, and MDAMB468 cancer cells. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.011

文献信息

• Cdk inhibitors having 3-hydroxychromen-4-one structure
  申请人：——

  公开号：US20030125356A1

  公开（公告）日：2003-07-03

  The present invention relates to a novel 3-hydroxychromen-4-one derivative of formula (1), pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase (“CDK”); to a process for preparing the compound of formula (1); and to a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. comprising the compound of formula (1) as an active component together with pharmaceutically acceptable carriers.

  本发明涉及一种新型的3-羟基香豆素-4-酮衍生物，其化学式为(1)，以及其在药理学上可接受的盐、水合物、溶剂合物或同分异构体，该衍生物可用作 Cyclin Dependent Kinase (“CDK”) 的抑制剂；还涉及制备化合物(1)的方法；以及一种用于抑制或治疗癌症和由细胞增殖引起的疾病，如炎症、血管狭窄、血管生成等的组合物，该组合物以化合物(1)作为活性成分，与药理学上可接受的载体一起使用。
• CDK INHIBITORS HAVING 3-HYDROXYCHROMEN-4-ONE STRUCTURE
  申请人：LG Life Sciences Ltd.

  公开号：EP1280789A1

  公开（公告）日：2003-02-05
• US6683095B2
  申请人：——

  公开号：US6683095B2

  公开（公告）日：2004-01-27
• [EN] CDK INHIBITORS HAVING 3-HYDROXYCHROMEN-4-ONE STRUCTURE<br/>[FR] INHIBITEURS DE CDK AVEC STRUCTURE 3-HYDROXYCHROMEN-4-UNE
  申请人：LG CHEM INVESTMENT LTD

  公开号：WO2001083469A1

  公开（公告）日：2001-11-08

  The present invention relates to a novel 3-hydroxychromen-4-one derivative of formula (1), pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase ('CDK'); to a process for preparing the compound of formula (1); and to a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. comprising the compound of formula (1) as an active component together with pharmaceutically acceptable carriers.
• 3-Hydroxychromones as cyclin-dependent kinase inhibitors: Synthesis and biological evaluation
  作者：Jinho Lee、Taesik Park、Shinwu Jeong、Kyoung-Hee Kim、Changyong Hong

  DOI：10.1016/j.bmcl.2006.12.011

  日期：2007.3

  A novel series of 3-hydroxychrornones were prepared and found to be CDK inhibitors. lsothiazolidine 1,1-dioxide analogues showed potent CDK1 and CDK2 inhibitory activities and inhibited proliferation of EJ, HCT 116, SW620, and MDAMB468 cancer cells. (c) 2006 Elsevier Ltd. All rights reserved.